Clinical Trial

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer inhibitors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-24; most recent amendment 2025-02-20.
Status change: Not Yet Recruiting → Recruiting 2023-06-18
Trial Details
NCT Number NCT05888870
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Sinocelltech Ltd.
Conditions Hemophilia A With Inhibitor
Enrollment 50 participants
Start Date 2023-11-22
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-24